Article Abstract

Risk stratification for Hepatitis B treatment in the molecular age

Authors: Sanjay R. Mehta, Alexander Kuo


Hepatitis B virus (HBV) is a world-wide scourge, affecting over 2 billion individuals, of which an estimated 240 million are chronic carriers of the virus (1). The burden of this disease is in the developing world, particularly in Asia and Africa, where diagnosis and monitoring can be difficult.